肿瘤创新药纳入全国医保目录的政策实施效果与思考

The Effect of Policy Implementation and Some Relevant Suggestions on the Inclusion of Innovative Tumor Drugs in the National Reimbursement Drug List

采用文献综述法建立社会影响、可及性、可负担性评估体系,评估肿瘤创新药(包括分子靶向药物、免疫治疗药物)自2017年逐步纳入国家医保目录的政策实施效果.结果发现,实施纳入国家医保目录政策后的正面社会影响突出、可及性获得满足、可负担性显著提高.建议在恶性肿瘤创新药纳入全国医保报销后,要考虑政策可持续、药物规范使用、保障不足或者滥用基金等问题.

To evaluate the implementation effect of the policy that innovative cancer drugs(including molecular targeted drugs and immunotherapy drugs)have been gradually included in the National Reimbursement Drug List(NRDL)since 2017.The social impact,accessibility and affordability evaluation system were established by literature review.After the implementation of the NRDL in 2017,the positive social impact,accessibility and affordability have been significantly improved.After malignant tumor innovative drugs were included in the NRDL,issues such as policy sustainability,rational medication,inadequate guarantee or abuse of funds should be considered.